Clinical and biochemical features of the course of COVID-19 in patients with arterial hypertension
- 作者: Mordyk A.1,2, Bagisheva N.1, Moiseeva M.1, Antipova E.1, Streltsova V.1
-
隶属关系:
- Omsk State Medical University, Ministry of Health of Russia
- National Medical Research Center for Phthisiopulmonology and Infectious Diseases, Ministry of Health of Russia
- 期: 卷 35, 编号 6 (2024)
- 页面: 79-82
- 栏目: From Practice
- URL: https://journals.rcsi.science/0236-3054/article/view/258454
- DOI: https://doi.org/10.29296/25877305-2024-06-16
- ID: 258454
如何引用文章
详细
Purpose. To study the clinical and biochemical features of the course of coronavirus infection (COVID-19) in patients with arterial hypertension (AH).
Material and methods. The retrospective study included 74 patients with COVID-19 treated in hospital (37 men and 37 women; median age: 55.0 [45.0, 59.0] years). The patients were divided into 2 groups: 1st (n=48) – patients with hypertension who had COVID-19; 2nd (n=26) – patients without concomitant cardiovascular pathology who had COVID-19. Patients were assessed daily (for 7 days) for the clinical symptoms of the disease with an assessment of complaints, respiratory rate, heart rate, SpO2. A study of the level of C-reactive protein (CRP), D-dimer, and ferritin was carried out initially, on the 3-5th and 8-10th days in the hospital.
Results. In group 1, compared with group 2, cough, shortness of breath, myalgia (with minimization of symptoms during treatment), as well as significantly higher values of CRP and D-dimer were statistically significantly more common. At the same time, cough, shortness of breath and myalgia in patients with COVID-19 and hypertension were more pronounced at the onset of the disease, in contrast to patients without hypertension. An increase in CRP and D-dimer indicators determines the severity of the condition of patients with comorbid pathology at the onset of the disease and requires timely hospitalization of this category of patients.
作者简介
A. Mordyk
Omsk State Medical University, Ministry of Health of Russia; National Medical Research Center for Phthisiopulmonology and Infectious Diseases, Ministry of Health of Russia
编辑信件的主要联系方式.
Email: ppi100@mail.ru
ORCID iD: 0000-0001-6196-7256
Professor, MD
俄罗斯联邦, Omsk; MoscowN. Bagisheva
Omsk State Medical University, Ministry of Health of Russia
Email: ppi100@mail.ru
ORCID iD: 0000-0003-3668-1023
Candidate of Medical Sciences
俄罗斯联邦, OmskM. Moiseeva
Omsk State Medical University, Ministry of Health of Russia
Email: ppi100@mail.ru
ORCID iD: 0000-0003-3458-9346
Candidate of Medical Sciences
俄罗斯联邦, OmskE. Antipova
Omsk State Medical University, Ministry of Health of Russia
Email: ppi100@mail.ru
俄罗斯联邦, Omsk
V. Streltsova
Omsk State Medical University, Ministry of Health of Russia
Email: ppi100@mail.ru
俄罗斯联邦, Omsk
参考
- Антипова Е.П., Моисеева М.В., Багишева Н.В. и др. COVID-19 в когорте пациентов с артериальной гипертензией: роль рецепторов ангиотензинпревращающего фермента. Забайкальский медицинский вестник. 2023; 1: 104–12 [Antipova E.P., Moiseeva M.V., Bagisheva N.V. et al Arterial hypertension and COVID-19: the role of angiotensin-converting enzyme receptors in infection. Transbaikal Medical Bulletin. 2023; 1: 104–12 (in Russ.)]. doi: 10.52485/19986173_2023_1_104
- Моисеева М.В., Багишева Н.В., Мордык А.В. и др. Что известно о влиянии артериальной гипертензии на течение COVID-19. Клинический разбор в общей медицине. 2022; 5: 6–9 [Moiseeva M.V., Bagisheva N.V., Mordyk A.V., et al. What is known about the impact of hypertension on the course of COVID-19. Clinical Review for General Practice. 2022; 5: 6–9 (in Russ.)]. doi: 10.47407/kr2022.3.5.00156
- Насонов Е.Л. Иммунопатология и иммунофармакотерапия коронавирусной болезни 2019. (COVID-19): фокус на интерлейкин-6. Научно-практическая ревматология. 2020; 58 (3): 245–61 [Nasonov E.L. Immunopathology and immunopharmacotherapy of coronavirus disease 2019 (COVID-19): focus on interleukin-6. Rheumatology Science and Practice. 2020; 58 (3): 245–61 (in Russ.).]. doi: 10.14412/1995-4484-2020-245-261
- Подзолков В.И., Брагина А.Е., Тарзиманова А.И. и др. Артериальная гипертензия и неблагоприятное течение COVID-19 среди госпитализированных больных: данные когортного исследования из России. Рациональная Фармакотерапия в Кардиологии. 2023; 19 (1): 4–10 [Podzolkov V.I., Bragina A.E., Tarzimanova A.I. et al. Arterial Hypertension and Severe COVID-19 in Hospitalized Patients: Data from a Cohort Study. Rational Pharmacotherapy in Cardiology. 2023; 19 (1): 4–10 (in Russ.)]. doi: 10.20996/1819-6446-2023-01-10
- Хабибулина М.М., Шамилов М.Д. Пандемия COVID-19: эмоциональное выгорание у медицинских сестер 3 года спустя. Медицинская сестра. 2024; 26 (2): 51–8 [Khabibulina M.M., Shamilov M.D. COVID-19 pandemic: Emotional burnout in nurses (3 years later). Meditsinskaya sestra. 2024; 26 (2): 51–8 (in Russ.)]. doi: 10.29296/25879979-2024-02-11
- Aziz M., Fatima R., Assaly R. Elevated interleukin-6 and severe COVID-19: A meta- analysis. J Med Virol. 2020; 92 (11): 2283. doi: 10.1002/jmv.25948
- Cao Y., Liu X, Xiong L., Cai K. Imaging and clinical features of patients with 2019 novel c oronavirus SARS-CoV-2: a systematic review and meta-analysis. J Med Virol. 2020; 92 (9): 1449–59. doi: 10.1002/jmv.25822
- Diao B., Wang C., Tan Y. et al. Reduction and functional exhaustion of T Cells in patients with coronavirus disease 2019 (COVID-19). MedRxiv. 2020: 827. doi: 10.1101/2020.02.18.20024364
- Mehta P., McAuley D.F., Brown M. et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020; 395 (10229): 1033–4. doi: 10.1016/S0140-6736(20)30628-0
- Ruan Q., Yang K., Wang W. et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020; 46 (5): 846–8. doi: 10.1007/s00134-020-05991
- Sun X., Wang T., Cai D. et al. Сytokine storm intervention in the early stages of COVID-19 pneumonia. Cytokine Growth Factor Rev. 2020; 53: 38–42. doi: 10.1016/j.cytogfr.2020.04.002
- Wang L. C-reactive protein levels in the early stage of COVID-19. Med Mal Infect. 2020; 50 (4): 332–4. doi: 10.1016/j.medmal.2020.03.007
- Wu C., Chen X., Cai Y. et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020; 180 (7): 934–43. doi: 10.1001/jamainternmed.2020.0994
- Yun H., Sun Z., Wu J. et al. Laboratory data analysis of novel coronavirus (COVID-19) screening in 2510 patients. Clin Chim Acta. 2020; 507: 94–7. doi: 10.1016/j.cca.2020.04.018
- Zhu Z., Cai T., Fan L. et al. Clinical value of immune-inflammatory parameters to assess the severity of coronavirus disease 2019. Int J Infect Dis. 2020; 96: 332–9. doi: 10.1016/j.ijid.2020.04.041
- Zhu J., Ji P., Pang J. et al. Clinical characteristics of 3,062 COVID-19 patients: a meta-analysis. J Med Virol. 2020; 92 (10): 1902–14. doi: 10.1002/jmv.25884